Beta-Hydroxyisovalerylshikonin

Research use only, not for human use.

Beta-Hydroxyisovalerylshikonin is an inhibitor of protein-tyrosine kinases such as v-Src and EGFR, and has been shown to induce apoptosis in several human tumor cell lines. Beta-Hydroxyisovalerylshikonin significantly decreased viability of HCT116 cells (IC50 values = 30.9 μg/mL).

Beta-Hydroxyisovalerylshikonin is an inhibitor of protein-tyrosine kinases such as v-Src and EGFR, and has been shown to induce apoptosis in several human tumor cell lines. Beta-Hydroxyisovalerylshikonin significantly decreased viability of HCT116 cells (IC50 values = 30.9 μg/mL).(In Vitro):The tyrosine kinase activities of a receptor for EGF (EGFR) and v-Src were strongly inhibited and that of KDR/Flk-1 was weakly inhibited by Beta-Hydroxyisovalerylshikonin. The IC50 values of Beta-Hydroxyisovalerylshikonin for EGFR and v-Src were approximately 0.7 microM and 1 microM, respectively.(In Vivo):In vivo experiments also proved the therapeutic effects of Beta-Hydroxyisovalerylshikonin on OA in mice, and Nrf2 is the target of Beta-Hydroxyisovalerylshikonin.

——

——

β-Hydroxyisovalerylshikonin

Angiogenesis

EGFR

EGFR

——

——

7415-78-3

388.416

C21H24O7

>98% (HPLC)

In Vitro:?DMSO : 10 mg/mL (25.75 mM)

CC(C)=CC[C@@H](OC(=O)CC(C)(C)O)C1=CC(=O)c2c(O)ccc(O)c2C1=O

——

(-20℃)

With Ice Pack

≥ 2 years